Gene Ther
Mol Biol Vol 1, 707-711. March, 1998.
Cdc25 protein phosphatase:
regulation and its role in cancer
Jens W. Eckstein
Mitotix, Inc., One Kendall Square,
Cambridge, MA 02139 USA
______________________________________________________________________________________
Correspondence: Jens W. Eckstein,
Tel: (617) 225-0001 x255, Fax: (617) 225-0005, E-mail: eckstein@mitotix.com
Summary
The family of the Cdc25
dual-specific protein tyrosine/threonine phosphatases is critically involved in
cell cycle control. The substrates of Cdc25 are cyclin-dependent kinases, which
are regulated by the phosphorylation of threonine and tyrosine residues. Cdc25
regulation and activity reveals a complex network of counter-balancing
mechanisms and puts it on the crossroads of fundamental cellular events like
cell proliferation, cell cycle arrest and apoptosis. Our present knowledge of
the biology and biochemistry of Cdc25 phosphatases makes them attractive
targets for drug discovery efforts: (a) they phase critical, non-redundant cell
cycle regulatory functions; (b) they are bona fide checkpoint genes; (c) they have
tight substrate specificities and a well-defined mechanism of catalysis; (d)
they are potential targets of at least two oncogenes (Raf1 and c-Myc) that are
frequently altered in human cancers; (e) they co-operate with other oncogenes
in cell transformation and thus are bona fide proto-oncogenes; and lastly (f)
their expression is altered in tumors.
I. Introduction: Cdc25 and the
cell cycle
The role of Cdc25 as an inducer of
mitosis first emerged from studies of yeast genetics that linked the
phosphorylation state of the Cdc2 cyclin-dependent kinase to the activity of a
protein phosphatase (Russell and Nurse, 1986). Later, the gene product of the
cdc25 gene was identified to be a dual-specificity phosphatase that removes
inhibitory phosphorylations of Cdc2, both from a highly conserved tyrosine
residue (Tyr15) and a less conserved threonine residue (Thr14, Figure 1). Homologs of the yeast gene were
identified in a wide variety of organisms. This functional conservation of
Cdc25 throughout evolution illustrates its fundamental role in controlling the
cell cycle.
The regulation of proteins of the
cyclin-dependent kinase (Cdk) family has been studied in great detail, and
several cdc25 genes have been identified in mammals. In humans the three
homologs that were isolated are Cdc25A, B and C. Cdc25 C is the mitotic
inducer; its substrate is the hyperphosphorylated complex of Cdc2/cyclin B. The
functions of Cdc25A and B are less clear, with their possible substrates
ranging from Cdk4/cyclin D (Terada et al., 1995), Cdk2/cyclin E and cyclin A
complexes (Hoffmann et al., 1994) to Cdc2/cyclin A and cyclin B complexes (for
a recent review on Cdc25 cell biology and biochemistry, see Draetta and
Eckstein, 1997).
Recent investigations into the
regulation of Cdc25 itself are beginning to shed light on an intruiging and
complex network of players (please refer to Figure 2 throughout the text). They place
Cdc25 squarely on the crossroads between cell proliferation, apoptosis,
mitogenic signal transduction, and cancer. This chapter reviews briefly the
emerging understanding of Cdc25 regulation and its implications for human
cancer.
II. Cdc25 is a phosphoprotein
The Cdc25 protein undergoes
phosphorylation during the cell cycle (Izumi et al., 1992), a step that
triggers its phosphatase activity. The phosphorylation of all three human
versions of Cdc25 is essential for cell cycle progression. Several
phosphorylation sites have been mapped, suggesting the possibility that more
than one kinase is involved in this regulation of Cdc25 by post-translational
modification.
Cdc25 can be phosphorylated by its
own substrate, cyclin-dependent kinases (Cdks). Cdc25C is phosphorylated and
activated by Cdc2/cyclin B in vitro. In vivo, this activation occurs at the G2/M transition, which
initiates mitosis (Hoffmann et al., 1993; Izumi and Maller, 1993; Strausfeld et
al., 1994). Cdc25A was later
Figure 1. Cdc25 is a dual-specificity protein phosphatase activating
cyclin-dependent kinases (Cdks)
Cdks bind to cyclins and are phosphorylated on three residues. Thr160 phosphorylation (Pa, shown in green) activates the kinase. The phosphorylations on Thr14 and Tyr15 (Pi, shown in red) are inhibitory and removed by Cdc25, resulting in an active kinase. The kinases Wee1 and Myt1 are counter-acting Cdc25 and phosphorylate Tyr15 and Thr14, respectively.


Figure 2 Cdc25 and the cell cycle.
This scheme summarizes the regulation
and function of human Cdc25A, B and C in the cell cyle, as described in the
text. Green arrows indicate induction, (de)phosphorylation or activation, red
lines inhibition. Proteins with a Ubi tag are degraded via the
ubiquitin-dependent pathway. Approximate timing of events and activity of
proteins is indicated by the brown dashed lines subdividing the cell cycle into
G0/G1, S, and G2/M phases.
shown to be phosphorylated by
Cdk2/cyclin E in vitro (Hoffmann et al., 1994). In vivo, hyperphosphorylation of Cdc25A occurs during the
S-phase (Jinno et al., 1994). These results suggest regulation of Cdc25 via a
self-amplifying feedback loop. Such a cooperative phenomenon has been cited to
explain the sharp rise of Cdc2 kinase activity at the G2/M transition (Hoffmann
et al., 1993; Izumi and Maller, 1993; Strausfeld et al., 1994).
In addition to Cdks, other kinases
are implicated in Cdc25 phosphorylation, as well.
For example, the Raf1 kinase turned
out to associate with Cdc25. Using double immunofluorescence microscopy, Cdc25A
and B were found to co-localize with Raf1 and Ras at the cell membrane
(Galaktionov et al., 1995), a process that is dependent on serum stimulation.
Raf1 kinase phosphorylates Cdc25A and B in vitro, leading to an increase in
phosphatase activity (Galaktionov et al., 1995).
In a two-hybrid screen experiment,
Raf1 also was found to be associated with members of the 14-3-3 protein family,
which in turn associated with Cdc25A and B (Conklin et al., 1995). 14-3-3
proteins have been implicated in a number of mitogenic signaling pathways,
including the kinase cascade that contains Raf1 (Fantl et al., 1994; Freed et
al., 1994).
Moreover, a role for 14-3-3 proteins
in the regulation of Cdc25 was reported in connection with DNA damage sensing
in cells. The response of cells to UV-induced DNA damage is multifaceted. It
involves induction of cyclin-dependent kinase inhibitors, such as p21Cip1/Waf1, as well as hyperphosphorylation
of the Cdks, and ultimately leads to cell cycle arrest (Poon et al., 1996).
Recently, a new pathway has been proposed that links the gene sensing DNA
damage in the yeast S. pombe—Rad3—to Cdc25 activity (Furnari et al., 1997;
Sanchez et al., 1997). Rad3 is related to the human ATM protein that is
defective in ataxia telangiectasia patients, a rare genetic disorder whose varied symptoms
include possibly a high risk of developing tumors (Xu and Baltimore, 1996).
DNA damage induces increased
phosphorylation of the Chk1 kinase by a Rad3-dependent process. Cdc25 is
potentially a direct target of Chk1, and Chk1's phosphorylation of a specific
serine residue (Ser216 in human Cdc25C) results in binding of Cdc25 to 14-3-3
protein (Peng et al., 1997). It was proposed that 14-3-3 binding sequesters
Cdc25C from functionally interacting with Cdc2, leading to a G2 arrest in the
cell cycle. Regulation of Cdc25 by spatial sequestering rather than inhibition
of the phosphatase activity seems to be the main effect of the phosphorylation
of Cdc25 via the Chk1 kinase. The Chk1 phosphorylation site is conserved in
Cdc25A and B, as well, suggesting that a similar regulatory mechanism is
involved in other DNA damage checkpoints earlier in the cell cycle.
The role of the 14-3-3 proteins in
connection with the Raf1 kinase is still unclear. One can speculate that 14-3-3
proteins act as docking sites—or adaptors—for both Cdc25 and Raf1,
and that subsequent phosphorylation of Cdc25 by Raf1 leads to the release and
activation of Cdc25. This example nicely illustrates the fine balance of
counter-acting processes in cell cycle regulation. Furthermore, it identifies
Cdc25C, and possibly Cdc25A and B, as bona fide checkpoint genes.
Yet other kinases have been reported
to phosphorylate Cdc25 protein, suggesting that there are additional mechanisms
for coordinating the regulation of cyclin-dependent kinases with various
mitotic processes, such as chromosome segregation (Kumagai and Dunphy, 1996).
III. Other regulatory mechanisms
The level of Cdc25 protein is
tightly regulated by both transcriptional and post-translational mechanisms
(Ducommun et al., 1990; Moreno et al., 1990). In humans, Cdc25A is expressed
early in the G1 phase of the cell cycle following serum stimulation of
quiescent fibroblasts (Jinno et al., 1994). Cdc25 B is expressed closer to the
G1/S transition, and Cdc25C is activated in G2 (Sadhu et al., 1990).
Recently, Galaktionov and colleagues
observed that Cdc25 mRNA became more abundant following activation of the Myc
proto-oncogene. They were able to show that Cdc25A, and possibly Cdc25B, are
physiologically relevant and direct targets of c-Myc (Galaktionov et al.,
1996). Their studies suggest furthermore that Cdc25 is a general mediator of
Myc function. Therefore, Cdc25 is not only essential to normal cell
proliferation but also for inducing Myc-dependent apoptosis.
Downregulation of Cdc25 was reported
to be achieved by at least two different mechanisms in the cell: repression and
ubiquitin-dependent degradation.
As an example for repression,
consider TGF-ß. Its effect on cyclin-dependent kinase activity has been
extensively studied as a model anti-mitogenic response, in particular in
connection with cyclin-dependent kinase inhibitors (CKIs). In a recent report,
Iavarone et al. conclude that induction of the cyclin-dependent kinase
inhibitor p15Ink4B and downregulation
of Cdc25A by TGF-ß constitute two complementary mechanisms of inhibition
of the cyclin D-dependent kinase (Iavarone and Massague, 1997). Their
experiments indicate that Cdc25A downregulation by TGF-ß occurs at
transcription; it remains to be determined whether Myc participates in this
process.
Ubiquitin-dependent degradation of
proteins is an important regulatory mechanism for all sorts of cellular
processes (reviewed in Ciechanover, 1994) and has been found to play a key role
in the degradation of the mitotic cyclins (Glotzer et al., 1991). In a study on
Cdc25 degradation in S.pombe, Nefsky and Beach isolated a gene named Pub1, which encodes
an E6-AP like protein (Nefsky and Beach, 1996). E6-AP belongs to a family of
ubiquitin ligases, or E3s, which assist in transferring a ubiquitin molecule or
a polyubiquitin chain to a target protein. Once the target protein is tagged
with ubiquitin, it is rapidly degraded by the 26S proteasome. Cdc25 was
ubiquitinated in a Pub1-dependent fashion, and loss of Pub1 function lead to
elevated levels of Cdc25 protein and increased Cdc25 activity in vivo.
IV. Cooperation of Ras and Myc
The regulation of Cdk activity
involves inhibitory small proteins (cyclin-dependent kinase inhibitors, or
CKIs) from the Ink and the Waf1/Kip1/Cip1 families. Recent findings suggest,
firstly, that the regulation of Cdc25 and the CKI proteins through Ras and Myc
is tightly interconnected and, secondly, that the cooperation of active Ras and
Myc leads to accumulation of G1 Cdk activity (Leone et al., 1997). Expression
of Myc and Ras results in a loss of p27Kip1
protein (probably through ubiquitin-dependent proteolysis) and leads to
increased Cdk2/cyclin E activity. At the same time, Cdc25A is induced by c-Myc
and activated by Raf1, a downstream target of Ras. This leads to a synergistic
effect in removing an inhibitory protein and inhibitory phosphorylations on
Cdk2/cyclin E, culminating in induction of S-phase.
Interestingly, the competition
between p21 and Cdc25 can be demonstrated directly in binding experiments. Saha
et al. identified a consensus sequence in p21 and Cdc25 that is important for
their binding to Cdk complexes (Saha et al., 1997). p21 protein directly
competes with Cdc25A and vice versa, suggesting that the two proteins utilise similar docking
sites on the Cdk/cyclin complexes.
V. Cdc25 and cancer
Cdc25A and B have oncogenic
properties. In rodent cells, human Cdc25A and Cdc25B, but not Cdc25C,
phosphatases cooperate with either an activated Ras allele or loss of Rb1 in
oncogenic focus formation (Galaktionov et al., 1995). Such transformants are
highly aneuploid, grow in soft agar, and form high-grade tumours in nude mice.
Based upon these criteria, Cdc25A and B are bona fide cellular proto-oncogenes.
Indeed, Cdc25B mRNA is expressed at
high levels in 32 percent of human primary breast cancers tested (Galaktionov
et al., 1995). Similar findings have come from breast cancer studies on Cdc25 A
(M. Loda et al., unpublished). Overexpression of Cdc25A and Cdc25B, but not
Cdc25C, has also been reported in more than 50 percent of tested squamous cell
carcinomas of the head and the neck (Gasparotto et al., 1997).
Given the tight connection between
Cdc25 and the well-known oncogenes Ras and Myc, overexpression and activation
of Cdc25 might be an important feature in cancer development, making Cdc25 an
attractive target for future cancer therapy.
Acknowledgement
I thank my wife, Gabrielle Strobel,
for editorial assistance.
References
Ciechanover, A. (1994). The ubiquitin-proteasome
proteolytic pathway. Cell 79, 13-21.
Conklin, D. S., Galaktionov, K., and
Beach, D. (1995).
14-3-3 proteins associate with cdc25 phosphatases. Proc Natl Acad Sci U S A 92, 7892-7896.
Draetta, G., and Eckstein, J. (1997). Cdc25 protein phosphatases in cell
proliferation. Biochim. Biophys. Acta 1332, M53-M63.
Ducommun, B., Draetta, G., Young, P.,
and Beach, D. (1990).
Fission yeast cdc25 is a cell-cycle regulated protein. Biochem Biophys Res
Commun 167, 301-309.
Fantl, W. J., Muslin, A. J., Kikuchi,
A., Martin, J. A., MacNicol, A. M., Gross, R. W., and Williams, L. T. (1994). Activation of Raf-1 by 14-3-3
proteins. Nature
371, 612-4.
Freed, E., Symons, M., Macdonald, S.
G., McCormick, F., and Ruggieri, R. (1994). Binding of 14-3-3 proteins to the protein kinase
Raf and effects on its activation. Science 265, 1713-6.
Furnari, B., Rhind, N., and Russell,
P. (1997). Cdc25
mitotic inducer targeted by chk1 DNA damage checkpoint kinase [In Process
Citation]. Science
277, 1495-7.
Galaktionov, K., Chen, X., and Beach,
D. (1996). Cdc25
cell-cycle phosphatase as a target of c-myc. Nature 382, 511-517.
Galaktionov, K., Jessus, C., and
Beach, D. (1995).
Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to
cell cycle activation. Genes & Dev 9, 1046-1058.
Galaktionov, K., Lee, A. K.,
Eckstein, J., Draetta, G., Meckler, J., Loda, M., and Beach, D. (1995). CDC25 phosphatases as potential
human oncogenes. Science 269, 1575-1577.
Gasparotto, D., Maestro, R.,
Piccinin, S., Vukosavljevic, T., Barzan, L., Sulfaro, S., and Boiocchi, M. (1997). Overexpression of CDC25A and
CDC25B in head and neck cancers. Cancer Res 57, 2366-8.
Glotzer, M., Murray, A. W., and
Kirschner, M. W. (1991). Cyclin is degraded by the ubiquitin pathway. Nature 349, 132-138.
Hoffmann, I., Clarke, P. R., Marcote,
M. J., Karsenti, E., and Draetta, G. (1993). Phosphorylation and activation of human cdc25-C by
cdc2--cyclin B and its involvement in the self-amplification of MPF at mitosis.
EMBO J 12, 53-63.
Hoffmann, I., Draetta, G., and
Karsenti, E. (1994).
Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E
dependent phosphorylation at the G1/S transition. EMBO J 13, 4302-4310.
Iavarone, A., and Massague, J. (1997). Repression of the CDK activator
Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK
inhibitor p15. Nature 387, 417-22.
Izumi, T., and Maller, J. L. (1993). Elimination of cdc2
phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol
Biol Cell 4,
1337-50.
Izumi, T., Walker, D. H., and Maller,
J. L. (1992).
Periodic changes in phosphorylation of the Xenopus cdc25 phosphatase regulate
its activity. Mol Biol Cell 3, 927-939.
Jinno, S., Suto, K., Nagata, A.,
Igarashi, M., Kanaoka, Y., Nojima, H., and Okayama, H. (1994). Cdc25A is a novel phosphatase
functioning early in the cell cycle. EMBO J 13, 1549-56.
Kumagai, A., and Dunphy, W. G. (1996). Purification and molecular cloning
of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273, 1377-80.
Leone, G., DeGregori, J., Sears, R.,
Jakoi, L., and Nevins, J. R. (1997). Myc and Ras collaborate in inducing accumulation of
active cyclin E/Cdk2 and E2F. Nature 387, 422-6.
Moreno, S., Nurse, P., and Russell,
P. (1990).
Regulation of mitosis by cyclic accumulation of p80cdc25 mitotic inducer in
fission yeast. Nature 344, 549-52.
Nefsky, B., and Beach, D. (1996). Pub1 acts as an E6-AP-like protein
ubiquitiin ligase in the degradation of cdc25. EMBO J. 15, 1301-1312.
Peng, C. Y., Graves, P. R., Thoma, R.
S., Wu, Z., Shaw, A. S., and Piwnica-Worms, H. (1997). Mitotic and G2 checkpoint control:
regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216
[In Process Citation]. Science 277, 1501-5.
Poon, R. Y. C., Jiang, W., Toyoshima,
H., and Hunter, T. (1996). Cyclin-dependent kinases are inactivated by a combination of p21 and
Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J Biol Chem 271, 13283-91.
Russell, P., and Nurse, P. (1986). cdc25+ functions as an inducer in
the mitotic control of fission yeast. Cell 45, 145-53.
Sadhu, K., Reed, S. I., Richardson,
H., and Russell, P. (1990). Human homolog of fission yeast cdc25 mitotic inducer is predominantly
expressed in G2. Proc Natl Acad Sci U S A 87, 5139-43.
Saha, P., Eichbaum, Q., Silberman, E.
D., Mayer, B. J., and Dutta, A. (1997). p21CIP1 and Cdc25A: competition between an inhibitor and
an activator of cyclin-dependent kinases. Mol Cell Biol 17, 4338-45.
Sanchez, Y., Wong, C., Thoma, R. S.,
Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S. J. (1997). Conservation of the chk1
checkpoint pathway in mammals: linkage of DNA damage to cdk regulation through
cdc25 [In Process Citation]. Science 277, 1497-501.
Strausfeld, U., Fernandez, A.,
Capony, J. P., Girard, F., Lautredou, N., Derancourt, J., Labbe, J. C., and
Lamb, N. J. (1994).
Activation of p34cdc2 protein kinase by microinjection of human cdc25C into
mammalian cells. Requirement for prior phosphorylation of cdc25C by p34cdc2 on
sites phosphorylated at mitosis. J Biol Chem 269, 5989-6000.
Terada, Y., Tatsuka, M., Jinno, S.,
and Okayama, H. (1995). Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced
by ultraviolet irradiation. Nature 376, 358-362.
Xu, Y. and Baltimore, D. (1996) Dual roles of ATM in the cellular
response to radiation and in cell growth control. Genes Dev 10, 2401-2410.